Business Wire

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8006, an Antibody Drug Conjugate Targeting Folate Receptor α for the Treatment of Advanced Solid Tumors

GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical study evaluating ...
PharmiWeb

Artis BioSolutions Announces Agreement to Acquire Syngoi Technologies to Deliver Next Generation Solutions for Synthetic DNA Technology

SAN DIEGO & BOSTON & BILBAO, Spain--(BUSINESS WIRE)--Artis BioSolutions (“Artis”), a San Diego-based advanced-therapies development and manufacturing company, today announced that it has entered into ...